-
-
-
Potential treatment targets for migraine: emerging options and future prospects Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Chia-Chun Chiang, Frank Porreca, Carrie E Robertson, David W Dodick
-
Sleep matters in anti-LGI1 encephalitis Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Anna Heidbreder
-
Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Amaia Muñoz-Lopetegi, Mar Guasp, Laia Prades, Eugenia Martínez-Hernández, Mireia Rosa-Justícia, Víctor Patricio, Thaís Armangué, Lorena Rami, Roger Borràs, Josefina Castro-Fornieles, Albert Compte, Carles Gaig, Joan Santamaria, Josep Dalmau
-
-
-
Thank you to The Lancet Neurology's peer reviewers in 2023 Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15
-
For a dementia diagnosis, clinical acumen must precede biomarkers Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 David S Knopman
-
The predictive value and clinical use of the neurological pupillary index Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Michael TC Poon, Ahmed Nouby, Paul M Brennan
-
Biomedical research must change as the climate does Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Grace Lindsay
-
The cultural history of dementia Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Hollie Sherwood-Martin
-
Monitoring patients with severe traumatic brain injury Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Ramon Diaz-Arrastia, Francis Bernard, Lori Shutter, William Barsan, Robert Silbergleit
-
Monitoring patients with severe traumatic brain injury Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Randall M Chesnut, Robert H Bonow, Walter Videtta
-
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Jeremy Chataway, Thomas Williams, Vivien Li, Ruth Ann Marrie, Daniel Ontaneda, Robert J Fox
-
Monitoring patients with severe traumatic brain injury Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Nathan Beucler
-
-
-
A future treatment horizon for migraine? Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Debbie L Hay
-
-
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Pushpa Narayanaswami, Donald B Sanders, Laine Thomas, Dylan Thibault, Jason Blevins, Rishi Desai, Andrew Krueger, Kathie Bibeau, Bo Liu, Jeffrey T Guptill, Vern C. Juel, Karissa L. Gable, Lisa D. Hobson-Webb, Janice M. Massey, Shruti Raja, C. Douglas Emmet, Yuebing Li, David Polston, Steven Shook, Debbie Hastings, Zaeem A. Siddiqi, Muhammed Abid Alvi, Haley Andonian, Michael Nicolle, Denise Hulley
-
Monitoring patients with severe traumatic brain injury – Authors' reply Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Jean-Francois Payen, Tobias Gauss, Antoine Vilotitch, Pierre Bouzat
-
-
The postmenopausal brain: no silver bullet, but silver linings Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Riley Bove, Hannah Silverman, Claudia Valeggia
-
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Giovanni B Frisoni, Cristina Festari, Federico Massa, Matteo Cotta Ramusino, Stefania Orini, Dag Aarsland, Federica Agosta, Claudio Babiloni, Barbara Borroni, Stefano F Cappa, Kristian S Frederiksen, Lutz Froelich, Valentina Garibotto, Alexander Haliassos, Frank Jessen, Anita Kamondi, Roy PC Kessels, Silvia D Morbelli, John T O'Brien, Markus Otto, Armand Perret-Liaudet, Francesca B Pizzini, Mathieu
-
-
Karen Duff: blazing a path in dementia research Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Priya Venkatesan
-
-
Monitoring patients with severe traumatic brain injury Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Nicolas Engrand, Loïc Miry
-
PROMISE of low-cost immunosuppressants for myasthenia gravis Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Sithara Ramdas, Jacqueline Palace
-
-
The predictive value and clinical use of the neurological pupillary index – Authors' reply Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Stefania Galimberti, Matteo Petrosino, Paola Rebora, Mauro Oddo, Fabio S Taccone, Giuseppe Citerio
-
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial Lancet Neurol. (IF 48.0) Pub Date : 2024-02-13 Cristina Tassorelli, Krisztián Nagy, Patricia Pozo-Rosich, Michel Lanteri-Minet, Sara Sacco, Tomáš Nežádal, Hua Guo, Rosa De Abreu Ferreira, Giovanna Forero, Joel M Trugman
-
ELEVATEd hope for patients after migraine treatment failure Lancet Neurol. (IF 48.0) Pub Date : 2024-02-13 Xiaonuo Xu, Liang Dong, Jiying Zhou
-
-
Brain capital is crucial for global sustainable development Lancet Neurol. (IF 48.0) Pub Date : 2024-01-24 Harris A Eyre, William Hynes, Rym Ayadi, Facundo Manes, Pawel Swieboda
Abstract not available
-
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study Lancet Neurol. (IF 48.0) Pub Date : 2024-01-24 Ralf Reilmann, Karen E Anderson, Andrew Feigin, Sarah J Tabrizi, Blair R Leavitt, Julie C Stout, Paola Piccini, Robin Schubert, Pippa Loupe, Anna Wickenberg, Beth Borowsky, Gail Rynkowski, Rita Volkinshtein, Thomas Li, Juha-Matti Savola, Michael Hayden, Mark Forrest Gordon
Background Laquinimod modulates CNS inflammatory pathways thought to be involved in the pathology of Huntington's disease. Studies with laquinimod in transgenic rodent models of Huntington's disease suggested improvements in motor function, reduction of brain volume loss, and prolonged survival. We aimed to evaluate the safety and efficacy of laquinimod in improving motor function and reducing caudate
-
WHO considers multiple sclerosis treatments essential Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Joanna Laurson-Doube, Anne Helme, Francesco Nonino, Thomas Piggott, Nick Rijke, Deanna Saylor
Abstract not available
-
Venglustat in GBA1-related Parkinson's disease Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Ari Zimran, Shoshana Revel-Vilk, Michal Becker-Cohen, Majdolen Istaiti, Arndt Rolfs
Abstract not available
-
Rapid genome sequencing for infantile-onset epilepsy within a national health-care setting Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Hannah K Robinson, Karen Stals, Sue Hill, Andrew Parrish, Emma L Baple
Abstract not available
-
The AfrAbia+plus Parkinson's Disease Genomic Consortium Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Wael Mohamed, Mohamed Abdelhalim Eltantawi, Yasser Mecheri, Yared Zenebe Zewde, Walaa A Kamel, Bashayer R Al-Mubarak, Karem H Alzoubi, Najib Kissani, Badrah S Alghamdi, Samia Ben Sassi
Abstract not available
-
Correction to Lancet Neurol 2023; 22: 1089–91 Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22
Abstract not available
-
Rhonda Voskuhl: basketball and bedside to bench to bedside Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Jules Morgan
Abstract not available
-
Challenges and opportunities in spinal muscular atrophy therapeutics Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Crystal J J Yeo, Eduardo F Tizzano, Basil T Darras
Spinal muscular atrophy was the most common inherited cause of infant death until 2016, when three therapies became available: the antisense oligonucleotide nusinersen, gene replacement therapy with onasemnogene abeparvovec, and the small-molecule splicing modifier risdiplam. These drugs compensate for deficient survival motor neuron protein and have improved lifespan and quality of life in infants
-
Laquinimod, Huntington's disease, and disease modification Lancet Neurol. (IF 48.0) Pub Date : 2024-01-24 Tiago A Mestre
Abstract not available
-
Reducing the uses of valproate: a controversial decision Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22
Abstract not available
-
Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Aravind Ganesh
Abstract not available
-
Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Alexandre Bejanin, Nicolas Villain
Abstract not available
-
Criteria for a biological definition of neuronal α-synuclein disease—a major conceptual step forward Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Clifford R Jack
Abstract not available
-
Has the time come to redefine Parkinson's disease? Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Sirwan K L Darweesh, Cristina Sampaio, Bastiaan R Bloem
Abstract not available
-
Parkinson's disease is a recognisable and useful diagnostic entity Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Jose A Obeso, Paolo Calabressi
Abstract not available
-
Deciphering spinal muscular atrophy: the need for more research Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Michelle Anne Farrar, Didu Sanduni Kariyawasam
Abstract not available
-
Venglustat in GBA1-related Parkinson's disease – Authors' reply Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 S Pablo Sardi
Abstract not available
-
A multipronged approach to advancing palliative care for people with intellectual disabilities Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Kwok Ying Chan, Kwok Wai Tsang
Abstract not available
-
A multipronged approach to advancing palliative care for people with intellectual disabilities – Author's reply Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Benzi M Kluger
Abstract not available
-
Parkinson's eponym Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Mark Weatherall
Abstract not available
-
-
A chance to prevent Alzheimer's disease sooner than you think Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Eric M Reiman, Jeffrey L Cummings, Jessica B Langbaum, Soeren Mattke, Robert C Alexander
Abstract not available
-
I am what I am Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Marco De Ambrogi
Abstract not available
-
Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Mikaël Mazighi, Martin Köhrmann, Robin Lemmens, Philippe A Lyrer, Carlos A Molina, Sébastien Richard, Danilo Toni, Yannick Plétan, Anouar Sari, Adeline Meilhoc, Martine Jandrot-Perrus, Sophie Binay, Gilles Avenard, Andrea Comenducci, Jean-Marie Grouin, James C Grotta
Background Antagonists of glycoprotein VI-triggered platelet activation used in combination with recanalisation therapies are a promising therapeutic approach in acute ischaemic stroke. Glenzocimab is an antibody fragment that inhibits the action of platelet glycoprotein VI. We aimed to determine and assess the safety and efficacy of the optimal dose of glenzocimab in patients with acute ischaemic